Aetos Pharma Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 29-07-2024
- Paid Up Capital ₹ 0.10 M
as on 29-07-2024
- Company Age 3 Year, 15 Days
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit -1036.84%
(FY 2023)
- Ebitda -1036.84%
(FY 2023)
- Net Worth -8.71%
(FY 2023)
- Total Assets -2.83%
(FY 2023)
About Aetos Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Nisarg Patel and Maheshkumar Patel serve as directors at the Company.
- CIN/LLPIN
U24304GJ2021PTC125647
- Company No.
125647
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Sep 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Aetos Pharma Private Limited offer?
Aetos Pharma Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Tablets, Anti Infective Drugs & Medicines, Antifungal Injection, Tablet & Syrup, Pain Relief Drugs & Pharmaceuticals, Arthritic Drugs, Cardiovascular Drugs & Medication, Immunosuppressive Drugs, Antiviral Drugs, Injectable Products.
Who are the key members and board of directors at Aetos Pharma?
Board Members(2)
Financial Performance and Corporate Structure Insights of Aetos Pharma.
Aetos Pharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 1036.84% decrease in profit. The company's net worth dipped by a decrease of 8.71%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aetos Pharma?
In 2023, Aetos Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sini Pharma Private Limited
Active
3 years 2 days Nisarg Patel and Maheshkumar Patel are mutual person
Blue Lotus Luxury Homes Llp
Active 7 years 1 month Nisarg Patel and Maheshkumar Patel are mutual person
Sini Brook Biotech Private Limited
Active 2 years 7 months Nisarg Patel and Maheshkumar Patel are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aetos Pharma?
Aetos Pharma has a workforce of 0 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aetos Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aetos Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
